ACADIA Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ACADIA Pharmaceuticals Inc. (ACAD) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income226.45-61.29-215.98-167.87-281.58-235.26-245.19
Depreciation & Amortization15.885.59-0.743.344.47-0.813.01
Stock Based Compensation67.0566.4268.2063.6284.420.000.00
Change in Working Capital4.1618.2439.34-24.828.532.35-8.20
Change in Accounts Receivable-0.47-36.072.17-16.12-12.470.000.00
Change in Inventory-49.55-28.812.42-4.21-3.320.000.00
Change in Accounts Payable-1.354.805.87-1.621.270.000.00
Change in Other Working Capital55.5378.2227.54-2.8825.550.000.00
Other Operating Activities-155.8258.7966.8564.47131.2183.620.00
Net Cash from Operating Activities157.7216.70-114.04-125.66-136.10-151.10-167.47
Investing Activities
Capital Expenditures-0.52-0.050.00-1.127.591.13-2.10
Purchases of Investments-176.5372.0573.24-492.80200.100.000.00
Sales/Maturities of Investments328.57-369.9973.24422.82200.10-164.71-69.39
Other Investing Activities146.520.000.000.000.000.000.00
Net Cash from Investing Activities-30.5432.0073.24-71.10192.51-165.84-71.49
Financing Activities
Common Stock Issued6.8525.138.2018.1681.00371.85306.65
Net Cash from Financing Activities6.8525.138.2018.1681.00371.85306.65
Summary
Effect of Forex Changes on Cash-0.09-0.020.010.01-0.010.000.00
Net Change in Cash133.9373.81-32.60-178.60137.4154.9267.69
Cash at Beginning of Period194.43120.62153.21331.80194.47139.5871.89
Cash at End of Period328.36-353.24120.62153.21331.87194.50139.58
Free Cash Flow157.2016.70-114.04-126.78-143.69-152.23-169.57
Supplemental Disclosures
Income Taxes Paid19.525.852.191.041.111.601.26